Antihypertensive and renoprotective actions of soluble epoxide hydrolase inhibition in ANG II-dependent malignant hypertension are abolished by pretreatment with L-NAME

Journal of Hypertension

Volumn 31, Issue 2, 2013, Pages 321-332

  Honetschlägerová, Zuzana ^a   Kitada, Kento ^b   Husková, Zuzana ^a   Sporková, Alexandra ^a   Kopkan, Libor ^a   Bürgelová, Marcela ^a   Varcabová, Šárka ^a   Nishiyama, Akira ^b   Hwang, Sung Hee ^c   Hammock, Bruce D ^c   Imig, John D ^d   Kramer, Herbert J ^e   Kujal, Petr ^a,f   Vernerová, Zdenka ^a,f   Červenka, Luděk ^a,g  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^b KAGAWA UNIVERSITY   (Japan)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e UNIVERSITY OF BONN   (Germany)

^f Department of Pathology   (Germany)

^g CHARLES UNIVERSITY   (Czech Republic)

Author keywords

cytochrome P 450 metabolites; epoxyeicosatrienoic acids; malignant hypertension; nitric oxide; nitric oxide synthase; renin angiotensin system; soluble epoxide hydrolase

Indexed keywords

4 [4 (3 ADAMANTAN 1 YL UREIDO)CYCLOHEXYL OXY]BENZOIC ACID; CYTOCHROME P450 1A1; DIHYDROXYICOSATRIENOIC ACID; EPOXIDE HYDROLASE; EPOXYICOSATRIENOIC ACID; HYDROLASE INHIBITOR; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; SOLUBLE EPOXIDE HYDROLASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; KIDNEY INJURY; MALIGNANT HYPERTENSION; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RAT; RENAL PROTECTION;

EID: 84872851462     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32835b50aa     Document Type: Article

References (47)

1. Campbell WB, Fleming I. Epoxyeicosatrienoic acids and endotheliumdependent response. Pfugers Arch 2010; 459:881-895.
2. Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 2002; 82:131-185.
3. Imig JD. Epoxides and soluble epoxide hydrolase in cardiovascular physiology. Physiol Rev 2012; 92:101-130.
4. Li J, Carroll MA, Chander PN, Falck JR, Sangras B, Stier CT. Soluble epoxide hydrolase inhibitor, AUDA, prevents early salt-sensitive hypertension. Front Biosci 2008; 13:3480-3487.
5. Huang H, Morisseau C, Wang JF, Yang T, Falck JR, Hammock BD, Wang MH. Increasing or stabilizing renal epoxyeicosatrienoic acid production attenuates abnormal renal function and hypertension in obese rats. Am J Physiol 2007; 293:F342-F349.
6. Sporkova A, Kopkan L, Varcabová A, Husková Z, Hwang SH, Hammock BD, et al. Role of cytochrome P450 metabolites in the regulation of renal function and blood pressure in 2-kidney, 1-clip hypertensive rats. Am J Physiol 2011; 300:R1468-R1475.
7. Neckár J, Kopkan L, Husková Z, Kolár F, Papousek F, Kramer HJ, et al. Inhibition of soluble epoxide hydrolase by cis-4-[4-(3-adamantan-Iylureido) cyclohexyl-oxy]benzoic acid exhibits antihypertensive and cardioprotective actions in transgenic rats with angiotensin II-dependent hypertension. Clin Sci 2012; 122:513-525.
8. Honetschlägerová Z, Husková Z, Vanourková Z, Sporková A, Kramer HJ, Hwang SH, et al. Renal mechanisms contributing to the antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats with inducible hypertension. J Physiol 2011; 589:207-219.
9. Honetschlägerová Z, Sporková A, Kopkan L, Husková Z, Hwang SH, Hammock BD, et al. Inhibition of soluble epoxide hydrolyse improves the impaired pressure-natriuresis relationship and attenuates the development of hypertension and hypertension-associated end-organ damage in Cyp1a1-Ren-2 transgenic rats. J Hypertens 2011; 29:1590-1601.
10. Capdevila JH, Falck JR, Imig JD. Role of the cytochrome P450 arachidonic acid monooxygenases in the control of systemic blood pressure and experimental hypertension. Kidney Int 2007; 72:683-689.
11. Hercule HC, Schunck WH, Gross V, Seringer J, Leung FP, Weldon SM, et al. Interaction between P450 eicosanoids and nitric oxide in the control of arterial tone in mice. Aterioscler Thromb Vasc Biol 2009; 29:54-60.
12. Kantachuvesiri S, Fleming S, Peters J, Peters B, Brooker G, Lammie AG, et al. Controlled hypertension, a transgenic toggle switch reveals differential mechanisms underlying vascular disease. J Biol Chem 2001; 276:36727-36733.
13. Vanourková Z, Kramer HJ, Husková Z, Vanecková I, Opocenský M, Certíková Chábová V, et al. AT1 receptor blockade is superior to conventional triple therapy in protecting against end-organ damage Cyp1a1-Ren-2 transgenic rats with inducible hypertension. J Hypertens 2006; 24:2465-2472.
14. Husková Z, Vanourková Z, Erbanová M, Thumová M, Opocenský M, Mullins JJ, et al. Inappropriately high circulating and intrarenal angiotensin II levels during dietary salt loading exacerbate hypertension in Cyp1a1-Ren-2 transgenic rats. J Hypertens 2010; 28:495-509.
15. Mitchell KD, Bagatell SJ, Miller CS, Mouton CR, Seth DM, Mullins JJ. Genetic clamping of renin gene expression induces hypertension and elevation of intrarenal II levels of graded severity in Cyp1a1-Ren2 transgenic rats. JRAAS 2006; 7:74-86.
16. Erbanová M, Thumová M, Husková Z, Vanecková I, Vanourková Z, Mullins JJ, et al. Impairment of the autoregulation of renal hemodynamics and of the pressure-natriuresis relationship precedes the development of hypertension in Cyp1a1-Ren-2 transgenic rats. J Hypertens 2009; 27:575-586.
17. Howard CG, Mitchell KD. Renal functional response to selective intrarenal renin inhibition in Cyp1a1-Ren-2 transgenic rats with ANG IIdependent malignant hypertension. Am J Physiol 2012; 302:F52-F59.
18. Zicha J, Kunes J, Vranková S, Jendeková L, Dobesová Z, Pintérová M, Pechánová O. Influence of pertussion toxin pretreatment on the development of L-NAME-induced hypertension. Physiol Res 2009; 58:751-755.
19. Verhagen AMG, Braam B, Boer P, Grone HJ, Koomans HA, Joles JA. Losartan-sensitive renal damage caused by chronic NOS inhibition does not involve increased renal angiotensin II concentrations. Kidney Int 1999; 56:222-231.
20. Kujal P, Chabova VC, Vernerova Z, Walkowska A, Kompanowska-Jezierska E, Sadowski J, et al. Similar renoprotection after reninangiotensin-dependent and-independent antihypertensive therapy in 5/6-nephrectomized Ren-2 transgenic rats: are there blood pressureindependent effects? Clin Exp Pharmacol Physiol 2010; 37:1159-1169.
21. Kurtz TW, Griffin KA, Bidani AK, Davisson RL, Hall JE. Recommendations for blood pressure measurements in humans and experimental animals. Part 2: blood pressure measurements in experimental animals. Hypertension 2005; 45:299-310.
22. Sasser JM, Moningka NC, Tsarova T, Baylis C. Nebivolol does not protect against 5/6 ablation/infarction induced chronic kidney disease in rats-comparison with angiotensin II receptor blockade. Life Sci 2012; 91:54-63.
23. Kopkan L, Hess A, Husková Z, Cervenka L, Navar LG, Majid DSW. High-salt intake enhances superoxide activity in eNOS knockout mice leading to the development of salt sensitivity. Am J Physiol 2010; 299:F656-F663.
24. Kopkan L, Husková Z, Vanourková Z, Thumová M, Skaroupková P, Cervenka L, Majid DSW. Superoxide and its interaction with nitric oxide modulates renal function in prehypertensive Ren-2 transgenic rats. J Hypertens 2007; 25:2257-2265.
25. Certíková Chábová V, Walkowska A, Kompanowska-Jezierska E, Sadowski J, Kujal P, Vernerová Z, et al. Combined inhibition of 20-hydroxyeicosatetraenoic acid formation and epoxyeicosatrienoic acids degradation attenuates hypertension and hypertension-induced end-organ damage in Ren-2 transgenic rats. Clin Sci 2010; 118:617-632.
26. Nakano Y, Hirano T, Uehara K, Nishibayashi S, Hattori K, Aihara M, Yamada Y. New rat model induced by antiglomerular basement membrane antibody shows severe glomerular adhesion in early stage and quickly progresss to end-stage renal failure. Pathol Int 2008; 58:361-370.
27. Vanecková I, Kujal P, Husková Z, Vanourková Z, Vernerová Z, Certí-ková Chábová V, et al. Effects of combined endothelin A receptor and renin-angiotensin system blockade on the course of end-organ damage in 5/6 nephrectomized Ren-2 hypertensive rats. Kidney Blood Press Res 2012; 35:382-392.
28. Chin SY, Wang CT, Majid DSW, Navar LG. Renoprotective effects of nitric oxide in angiotensin II-induced hypertension in the rat. Am J Physiol 1998; 274:F876-F882.
29. Navar LG, Ichihara A, Chin SY, Imig JD. Nitric oxide-angiotensin II interactions in angiotensin II-dependent hypertension. Acta Physiol Scand 2000; 168:139-147.
30. Patterson ME, Mullins JJ, Mitchell KD. Renoprotective effects of neuronal NOS-derived nitric oxide and cyclooxygenase-2 metabolites in transgenic rats with inducible malignant hypertension. Am J Physiol 2008; 294:F205-F211.
31. Wilcox CS. L-Arginine-nitrix oxide pathway. In: Seldin DW, Giebisch G, editors. The kidney: physiology and pathophysiology. Philadelphia: Lippincott Williams & Wilkins; 2000. pp. 849-872.
32. Kone BC. Nitric oxide synthesis in the kidney:isoforms, biosynthesis, and functions in health. Semin Nephrol 2004; 24:299-315.
33. Madhun ZT, Goldthwait DA, McKay D, Hopfer U, Douglas JG. An epoxygenase metabolite of arachidonic acid mediates angiotensin II-induced rises in cytosolic calcium in rabbit proximal tubule epithelial cells. J Clin Invest 1991; 88:456-461.
34. Sakairi Y, Jacobson HR, Noland DT, Capdevila JH, Falck JR, Breyer MD. 5,6-EET inhibits ion transport in collecting duct by stimulating endogenous prostaglandin synthesis. Am J Physiol 1995; 268:F931-F939.
35. Zhao X, Yamamoto T, Newman JW, Kim IH, Watanabe T, Hammock BD, et al. Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. J Am Soc Nephrol 2004; 15:1244-1253.
36. Imig JD, Zhao X, Zaharis CZ, Olearczyk JJ, Pollock DM, Newman JW, et al. An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension 2005; 46:975-981.
37. Castrop H, Höcherl K, Kurtz A, Schweda F, Todorov V, Wagner C. Physiology of kidney renin. Physiol Rev 2010; 90:607-673.
38. Hall JE, Brands MW. The renin-angiotensin-aldosterone system: renal mechanisms and circulatory homeostasis. In: Seldin DW, Giebisch G, editors. The kidney: physiology and pathophysiology. Philadelphia: Lippincott Williams & Wilkins; 2000. pp. 1009-1046.
39. Schweda F, Kurtz A. Regulation of renin release by local and systemic factors. Rev Physiol Biochem Pharmacol 2011; 161:1-44.
40. Zatz R, Baylis C. Chronic nitric oxide inhibition model six years on. Hypertension 1998; 32:958-964.
41. Torok J. Participation of nitric oxide in different models of experimental hypertension. Physiol Res 2008; 57:813-825.
42. Kopkan L, Cervenka L. Renal interactions of renin-angiotensin system, nitric oxide and superoxide anion: implications in the pathophysiology of salt-sensitivity and hypertension. Physiol Res 2009; 58 (Suppl 2):S55-S57.
43. Zhou X, Frohlich ED. Differential effects of antihypertensive drugs on renal and glomerular hemodynamics and injury in the chronic nitrixoxide- suppressed rat. Am J Nephrol 2005; 25:138-152.
44. Ribeiro MO, Antune E, De Nucci G, Lovisolo SM, Zatz R. Chronic inhibition of nitric oxide synthesis: A new model of arterial hypertension. Hypertension 1992; 20:298-303.
45. Salazar FJ, Pinilla JM, López F, Romero JC, Quesada T. Renal effects of prolonged synthesis inhibition of endothelium-derived nitric oxide. Hypertension 1992; 20:113-117.
46. Jover B, Herizi A, Ventre F, Dupont M, Mimran A. Sodium and angiotensin in hypertension induced by long-term nitric oxide blockade. Hypertension 1993; 21:944-948.
47. Navarro-Cid J, Sanchez A, Sáiz J, Ruilope LM, García-Estan J, Romero JC, et al. Hormonal, renal and metabolic alterations during hypertension induced by crhonic inhibition of NO in rats. Am J Physiol 1994; 267:R1516-R1521.